Dr. Julie Krystal
Claim this profileThe Steven and Alexandra Cohen Children's Medical Center of New York
Area of expertise
Neuroblastoma
Julie Krystal has run 17 trials for Neuroblastoma. Some of their research focus areas include:
Diffuse Hemispheric Glioma
Julie Krystal has run 16 trials for Diffuse Hemispheric Glioma. Some of their research focus areas include:
Affiliated Hospitals
The Steven And Alexandra Cohen Children's Medical Center Of New York
Cohen Children's Medical Center Of New York
Clinical Trials Julie Krystal is currently running
DAY101
for Langerhans Cell Histiocytosis
This trial tests the safety and effectiveness of tovorafenib (DAY101) in children and young adults with Langerhans cell histiocytosis that is worsening, has returned, or does not respond to other treatments. Tovorafenib is taken orally and works by blocking enzymes needed for cancer cell growth. The study aims to find the best dose and observe the response and side effects over time.
Recruiting
1 award
Phase 2
28 criteria
Dinutuximab + Chemotherapy
for High-Risk Neuroblastoma
This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. Dinutuximab is a monoclonal antibody that binds to a molecule called GD2, which is found on the surface of neuroblastoma cells, but is not present on many healthy or normal cells in the body. When dinutuximab binds to the neuroblastoma cells, it helps signal the immune system to kill the tumor cells. This helps the cells of the immune system kill the cancer cells, this is a type of immunotherapy. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during Induction therapy. Chemotherapy drugs administered during Induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of 5 cycles of Induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on Extended Induction. During Extended Induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following, transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of Induction. The final stage of therapy is Post-Consolidation. During Post-Consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to Induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Recruiting
2 awards
Phase 3
7 criteria
More about Julie Krystal
Clinical Trial Related
9 years of experience running clinical trials · Led 24 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Julie Krystal has experience with
- Temozolomide
- Dinutuximab
- Irinotecan
- Larotrectinib
- Palbociclib
- Erdafitinib
Breakdown of trials Julie Krystal has run
Neuroblastoma
Diffuse Hemispheric Glioma
Cancer
Brain Tumor
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Julie Krystal specialize in?
Julie Krystal focuses on Neuroblastoma and Diffuse Hemispheric Glioma. In particular, much of their work with Neuroblastoma has involved Stage IV patients, or patients who are MYC positive.
Is Julie Krystal currently recruiting for clinical trials?
Yes, Julie Krystal is currently recruiting for 3 clinical trials in New Hyde Park New York. If you're interested in participating, you should apply.
Are there any treatments that Julie Krystal has studied deeply?
Yes, Julie Krystal has studied treatments such as Temozolomide, Dinutuximab, Irinotecan.
What is the best way to schedule an appointment with Julie Krystal?
Apply for one of the trials that Julie Krystal is conducting.
What is the office address of Julie Krystal?
The office of Julie Krystal is located at: The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York 11040 United States. This is the address for their practice at the The Steven and Alexandra Cohen Children's Medical Center of New York.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.